Curcumin (Turmeric)

Multiple RCTs and meta-analyses support modest relief of osteoarthritis pain, comparable in some trials to NSAIDs. Broader anti-inflammatory and anti-cancer claims rest on cell and animal work that curcumin's pharmacology makes hard to trust.

Curcumin is the most-published natural compound in modern biomedical literature and simultaneously the standing example medicinal chemists use for a molecule that looks active in every assay and works in almost none of them.

The chemistry problem is specific and worth understanding. Curcumin is what is known as a PAINS compound — pan-assay interference — meaning it produces apparent hits in screening assays through non-specific mechanisms: it is unstable, chemically reactive, fluorescent, and prone to disrupting membranes. It also has terrible bioavailability, being poorly absorbed, rapidly conjugated by the liver, and swiftly excreted. A landmark review in the *Journal of Medicinal Chemistry* laid out the case that curcumin has never been shown to be a specific, useful drug candidate despite the thousands of positive papers.

And yet the clinical picture is not empty. Curcumin has a genuine track record in one place: osteoarthritis pain. Multiple randomised trials, and meta-analyses pooling them, find meaningful reductions in knee pain and stiffness — several reporting effects comparable to ibuprofen or diclofenac, with fewer gastrointestinal side effects. The trials are mostly small, many use proprietary formulations from companies with an interest in the result, and the effect is modest. But the direction has been consistent enough across enough independent groups that dismissing it entirely is unfair.

How to hold both facts: the joint-pain finding is a clinical observation that stands on its own trial evidence, whatever the mechanism turns out to be. The sweeping claims — cancer prevention, Alzheimer's, depression, "reduces inflammation" as a general lifestyle proposition — rest almost entirely on the cell and rodent work that the pharmacology makes untrustworthy.

If you want to try it for joints, the formulation is not optional. Plain turmeric in food delivers almost nothing systemically. Use a bioavailability-enhanced product — piperine-combined, phytosome, or nanoparticle — at 500-1,500 mg of curcuminoids daily with food, and give it eight weeks. And take the interactions seriously: curcumin has genuine antiplatelet activity and inhibits several drug-metabolising enzymes, so it is not a free addition if you take anticoagulants.

How it works

Curcumin inhibits NF-κB, the master transcription factor for inflammatory signalling, and downstream mediators including COX-2 and several interleukins. The catch is bioavailability: unformulated curcumin is poorly absorbed, rapidly metabolised, and quickly excreted, so plasma concentrations after an oral dose sit far below what the cell studies used.